Shweta Singh1, Renuka Sinha2, Mayank Kaushik3. 1. Obstetrics and Gynaecology Department, V.M.M.C. & Safdarjang Hospital, New Delhi, India ; D.D.U Hospital, New Delhi, India ; 108, New Gandhi Nagar, Ghaziabad, U.P India. 2. Unit Head Department of Obstetrics and Gynaecology, V.M.M.C. & Safdarjang Hospital, D II/172, West Kidwai Nagar, New Delhi, 110023 India ; Rama Medical College, Ghaziabad, U.P India. 3. 108, New Gandhi Nagar, Ghaziabad, U.P India ; Department of Dermatology, E.S.I.C. Basaidarapur, Delhi, India.
Abstract
OBJECTIVE: To study the role of low molecular weight heparin (LMWH) in perinatal outcome. METHODS: A randomized, case control study was conducted at Safdarjang hospital, New Delhi. Patients were recruited from Sept. 2011 to May 2013 and were followed up till delivery. Thirty cases and controls were enrolled which comprised non-thrombophilic patients with previous history of preeclampsia, fetal growth restriction, abruption, and stillbirth (>20 weeks). Study group received daily single dose of LMWH depending upon the weight, subcutaneously; it was started before 15 weeks of gestation and continued up to 36 weeks. Nursery/NICU admission, APGAR score at 0 and 5 min, birth weight, gestational age at delivery, mode of delivery were observed among the interventional and control groups. RESULT: There was substantial reduction (80 %) in nursery/NICU admission. The mean gestational age and birth weight of the cases were observed to be higher as compared to those of control (38.05 ± 2.02 vs. 37.58 ± 2.06 weeks and 2770 ± 400 vs. 2530 ± 0.533 g). CONCLUSION:Prophylactic LMWH before 15 weeks of gestation improved the perinatal outcome in non-thrombophilic pregnant women.
RCT Entities:
OBJECTIVE: To study the role of low molecular weight heparin (LMWH) in perinatal outcome. METHODS: A randomized, case control study was conducted at Safdarjang hospital, New Delhi. Patients were recruited from Sept. 2011 to May 2013 and were followed up till delivery. Thirty cases and controls were enrolled which comprised non-thrombophilicpatients with previous history of preeclampsia, fetal growth restriction, abruption, and stillbirth (>20 weeks). Study group received daily single dose of LMWH depending upon the weight, subcutaneously; it was started before 15 weeks of gestation and continued up to 36 weeks. Nursery/NICU admission, APGAR score at 0 and 5 min, birth weight, gestational age at delivery, mode of delivery were observed among the interventional and control groups. RESULT: There was substantial reduction (80 %) in nursery/NICU admission. The mean gestational age and birth weight of the cases were observed to be higher as compared to those of control (38.05 ± 2.02 vs. 37.58 ± 2.06 weeks and 2770 ± 400 vs. 2530 ± 0.533 g). CONCLUSION: Prophylactic LMWH before 15 weeks of gestation improved the perinatal outcome in non-thrombophilic pregnant women.
Authors: Marc A Rodger; Michael Paidas; Claire McLintock; McLintock Claire; Saskia Middeldorp; Susan Kahn; Ida Martinelli; William Hague; Karen Rosene Montella; Ian Greer Journal: Obstet Gynecol Date: 2008-08 Impact factor: 7.661
Authors: L Robertson; O Wu; P Langhorne; S Twaddle; P Clark; G D O Lowe; I D Walker; M Greaves; I Brenkel; L Regan; I A Greer Journal: Br J Haematol Date: 2006-01 Impact factor: 6.998